Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination Therapy

Cancer Discovery(2024)10.1158/2159-8290.cd-23-0110Source: DataRank Database

Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination Therapy is a research paper published in Cancer Discovery (2024). On theSindex it has a DataRank of 0. It has been cited 45 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access45 citations

Download PDF

Cite:

Linked data & code

uniprot pdb doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)Impact (FWCI 7.11)OA: bronzeTopics (31)IDs (PubMed, PMC, OpenAlex)Annotations (3)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (16)

Daniel Cameron ORCID,Helen S. Mueller ORCID,Phillip Demarest ORCID,Nadia Zaffaroni ORCID,Noemi Arrighetti ORCID

Live enrichment

PubMed:38315003 PMC:PMC11147720 OpenAlex:https://openalex.org/W4391541073

National Institutes of Health

Grant: T32 GM007739

National Institutes of Health

Grant: R01 CA214812

National Institutes of Health

Grant: P30 CA08748

NCI NIH HHS

Grant: R01 CA204396

NCI NIH HHS

Grant: P50 CA217694

NCI NIH HHS

Grant: P30 CA008748

Maggies Mission

FWCI

7.11

Citation Percentile

1.0%

Citation Trend

2023

2024

2025

2026

bronze

journalhttps://aacrjournals.org/cancerdiscovery/article-pdf/doi/10.1158/2159-8290.CD-23-0110/3412551/cd-23-0110.pdf

publisherhttps://aacrjournals.org/cancerdiscovery/article-pdf/doi/10.1158/2159-8290.CD-23-0110/3412551/cd-23-0110.pdf

publisherhttps://aacrjournals.org/cancerdiscovery/article-pdf/14/6/965/3458454/965.pdf

journalhttps://doi.org/10.1158/2159-8290.cd-23-0110

repositoryhttps://pubmed.ncbi.nlm.nih.gov/38315003

Fields of Study

Chromatin Remodeling and CancerMechanisms of cancer metastasisProtein Degradation and Inhibitors

MeSH Terms

Enhancer of Zeste Homolog 2 ProteinSMARCB1 ProteinAnimalsBenzamidesBiphenyl CompoundsHumansMorpholinesMutationPyridonesDrug Resistance, NeoplasmEpigenesis, GeneticCell Line, TumorMice

Keywords

EpigeneticsEZH2Epigenetic therapyResistance (ecology)Combination therapyDrug resistanceComputational biologyBioinformaticsMedicineCancer researchBiologyGeneticsDNA methylationGeneGene expression

Sustainable Development Goals

SDG 0: Good health and well-being

Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination Therapy

FAIR Checklist

Authors (16)

Funding (7 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)